|March 13, 2013|
|15:45 EDT||NAVB, NAVB||Navidea to host conference call|
Conference call to discuss FDA approval of Lymphoseek Injection will be held on March 13 at 4 pm.
News For NAVB From The Last 14 Days
|September 2, 2015|
|07:33 EDT||NAVB||Navidea announces dual listing on Tel Aviv Stock Exchange|
Navidea Biopharmaceuticals announced that the Tel Aviv Stock Exchange has approved the new listing of Navidea's common stock on the TASE beginning on Tuesday, September 8 under the ticker symbol NAVB. The company's common stock will be listed on both the NYSE MKT in the United States and the TASE in Israel. The company also announced that, based upon Navidea's current market capitalization, it expects its shares to be subject to inclusion in five TASE equity indexes.
|07:27 EDT||NAVB||Sidoti to hold a conference|
2015 Sidoti Emerging Growth Conference is being held in New York on September 2.
|August 24, 2015|
|07:32 EDT||NAVB||Navidea to register shares for dual listing on TASE|
Navidea Biopharmaceuticals announced that it has filed an application for registration of shares of its common stock for dual listing on the Tel-Aviv Stock Exchange, or TASE. Dual listing on the TASE is allowed in the U.S. and Israel without any additional regulatory requirements for companies whose shares are listed on certain accredited stock exchanges outside of Israel, including the NYSE MKT.
|August 20, 2015|
|07:31 EDT||NAVB||Navidea reports publication of Lymphoseek comparative results in pain study|
Subscribe for More Information